A Study of Olaparib and Cediranib in Ovarian Cancer

March 23, 2017
Christina M. Annunziata, MD, PhD

Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.